SHC on Nasdaq
Sotera Health Co
In its 2026 annual report the company says: “We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world.”5 It is headquartered in Wilmington, United States.2 Its shares trade on Nasdaq under the symbol SHC.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Progyny, Inc., Tivity Health or VIEMED HEALTHCARE, INC., or pick any stock.
- TickerSHC on Nasdaq2
- IndustryServices-Misc Health & Allied Services, NEC2
- HeadquartersWilmington, United States2
- Incorporated inDE3
- Business address9100 South Hills Blvd, Suite 300, Broadview Heights, Oh 441473
- Filer categoryLarge accelerated filer3
- Legal formLimited Liability Company2
- LEI549300OVT7MBXFLOFU202
- StatusActive2
- LEI statusIssued and current2
- Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 57124062
See how the biggest companies compare on our leaderboards
We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health ® . We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. In 2025, our customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers’ manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of our services are necessary for our customers to satisfy …5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
55.5%Gross margin6
6.7%Net margin6
5.7%Revenue growth, 20256
12.9%Return on equity6
3.51×Debt to equity6
$149.2MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Service brought in 86% of the revenue Sotera Health Co broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Service | $905.6M | $941.8M | $995.8M |
| Product | $143.7M | $158.6M | $167.9M |
Business segments
Sterigenics brought in 65% of the revenue Sotera Health Co broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Sterigenics | $667.1M | $697.9M | $755.8M |
| Nelson Labs | $221.7M | $229.2M | $220.2M |
| Nordion | $160.5M | $173.4M | $187.6M |
Regions
United States brought in 54% of the revenue Sotera Health Co broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $591.0M | $616.7M | $629.5M |
| Europe | $187.5M | $196.0M | $232.2M |
| Canada | $192.1M | $208.9M | $221.9M |
| Other Geographical Areas | $78.7M | $78.9M | $79.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue45¢$518.1M
- Selling, general and admin22¢$252.8M
- Other costs21¢$245.3M
- Income tax6¢$69.6M
- Profit7¢$77.9M
Out of $1.2B in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Capital spending48¢$138.0M
- Kept or used elsewhere52¢$149.2M
Out of $287.2M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total net revenues | $1.2B | $1.1B | $1.0B |
| Total cost of revenues | $518.1M | $498.1M | $472.1M |
| Gross profit | $645.5M | $602.3M | $577.2M |
| Selling, general and administrative expenses | $252.8M | $242.6M | $236.7M |
| Amortization of intangible assets | $30.7M | $62.0M | $63.8M |
| Interest expense, net | $155.7M | $164.7M | $142.9M |
| Loss on refinancing of debt | $1.5M | $24.2M | $0 |
| Foreign exchange loss | $947.0K | $199.0K | $159.0K |
| Other income, net | -$8.5M | -$5.3M | -$7.4M |
| Income before income taxes | $147.5M | $113.9M | $106.0M |
| Provision for income taxes | $69.6M | $69.5M | $54.7M |
| Net income | $77.9M | $44.4M | $51.4M |
| Pension and post-retirement benefits (net of taxes of $600, $2,804 and $(3,420), respectively) | $2.4M | $8.5M | -$10.5M |
| Interest rate derivatives (net of taxes of $(718), $(1,856) and $(5,467), respectively) | -$2.1M | -$5.4M | -$15.7M |
| Foreign currency translation | $98.1M | -$118.6M | $40.2M |
| Comprehensive income (loss) | $176.4M | -$71.2M | $65.3M |
| Basic (in dollars per share) | $0.27 | $0.16 | $0.18 |
| Diluted (in dollars per share) | $0.27 | $0.16 | $0.18 |
| Basic (in shares) | 284.0M shares | 282.8M shares | 281.0M shares |
| Diluted (in shares) | 286.4M shares | 284.9M shares | 283.2M shares |
| Pension and post-retirement benefits, tax | $600.0K | $2.8M | -$3.4M |
| Interest rate swaps, tax | -$718.0K | -$1.9M | -$5.5M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $344.6M | $277.2M | |||
| Restricted cash short-term | $1.8M | $1.6M | |||
| Accounts receivable, net of allowance for uncollectible accounts of $2,968 and $2,532 as of December 31, 2025 and 2024, respectively | $139.3M | $140.3M | |||
| Inventories, net | $54.4M | $49.2M | |||
| Prepaid expenses and other current assets | $65.2M | $51.0M | |||
| Income taxes receivable | $8.0M | $6.7M | |||
| Total current assets | $613.4M | $526.0M | |||
| Property, plant, and equipment, net | $1.1B | $1.0B | |||
| Operating lease assets | $33.4M | $27.6M | |||
| Deferred income taxes | $3.9M | $2.9M | |||
| Post-retirement assets | $53.8M | $42.5M | |||
| Other assets | $36.7M | $37.1M | |||
| Other intangible assets, net | $288.2M | $317.7M | |||
| Goodwill | $1.1B | $1.1B | $1.1B | ||
| Total assets | $3.3B | $3.1B | |||
| Accounts payable | $78.0M | $55.1M | |||
| Accrued liabilities | $124.7M | $90.5M | |||
| Deferred revenue | $18.0M | $15.1M | |||
| Current portion of long-term debt | $14.0M | $14.8M | |||
| Current portion of finance lease obligations | $3.5M | $2.9M | |||
| Current portion of operating lease obligations | $5.8M | $5.1M | |||
| Income taxes payable | $5.7M | $7.6M | |||
| Total current liabilities | $249.6M | $191.0M | |||
| Long-term debt | $2.1B | $2.2B | |||
| Finance lease obligations, less current portion | $93.8M | $95.3M | |||
| Operating lease obligations, less current portion | $29.9M | $24.5M | |||
| Noncurrent asset retirement obligations | $53.5M | $49.3M | |||
| Deferred lease income | $17.1M | $16.8M | |||
| Post-retirement obligations | $8.1M | $7.9M | |||
| Noncurrent liabilities | $7.4M | $4.4M | |||
| Deferred income taxes | $71.1M | $69.5M | |||
| Total liabilities | $2.7B | $2.7B | |||
| Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at December 31, 2025 and 2024 | $2.9M | $2.9M | |||
| Preferred stock, with $0.01 par value, 120,000 shares authorized; no shares issued at December 31, 2025 and 2024 | $0 | $0 | |||
| Treasury stock, at cost (1,666 and 2,571 shares at December 31, 2025 and 2024, respectively) | -$17.0M | -$23.4M | |||
| Additional paid-in capital | $1.3B | $1.2B | |||
| Retained deficit | -$532.1M | -$610.0M | |||
| Accumulated other comprehensive loss | -$109.8M | -$208.3M | |||
| Total equity | $606.0M | $404.9M | $443.7M | $350.2M | |
| Total liabilities and equity | $3.3B | $3.1B | |||
| Allowance for uncollectible accounts | $3.0M | $2.5M | |||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |||
| Common stock, shares authorized (in shares) | 1.2B shares | 1.2B shares | |||
| Common stock, shares issued (in shares) | 286.0M shares | 286.0M shares | |||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | |||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |||
| Treasury stock (in shares) | 1.7M shares | 2.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 | 2020-11-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $344.6M | $277.2M | ||||
| Restricted cash short-term | $1.8M | $1.6M | ||||
| Accounts receivable, net of allowance for uncollectible accounts of $2,968 and $2,532 as of December 31, 2025 and 2024, respectively | $139.3M | $140.3M | ||||
| Inventories, net | $54.4M | $49.2M | ||||
| Prepaid expenses and other current assets | $65.2M | $51.0M | ||||
| Income taxes receivable | $8.0M | $6.7M | ||||
| Total current assets | $613.4M | $526.0M | ||||
| Property, plant, and equipment, net | $1.1B | $1.0B | ||||
| Operating lease assets | $33.4M | $27.6M | ||||
| Deferred income taxes | $3.9M | $2.9M | ||||
| Post-retirement assets | $53.8M | $42.5M | ||||
| Other assets | $36.7M | $37.1M | ||||
| Other intangible assets, net | $288.2M | $317.7M | ||||
| Goodwill | $1.1B | $1.1B | $1.1B | |||
| Total assets | $3.3B | $3.1B | ||||
| Accounts payable | $78.0M | $55.1M | ||||
| Accrued liabilities | $124.7M | $90.5M | ||||
| Deferred revenue | $18.0M | $15.1M | ||||
| Current portion of long-term debt | $14.0M | $14.8M | ||||
| Current portion of finance lease obligations | $3.5M | $2.9M | ||||
| Current portion of operating lease obligations | $5.8M | $5.1M | ||||
| Income taxes payable | $5.7M | $7.6M | ||||
| Total current liabilities | $249.6M | $191.0M | ||||
| Long-term debt | $2.1B | $2.2B | ||||
| Finance lease obligations, less current portion | $93.8M | $95.3M | ||||
| Operating lease obligations, less current portion | $29.9M | $24.5M | ||||
| Noncurrent asset retirement obligations | $53.5M | $49.3M | ||||
| Deferred lease income | $17.1M | $16.8M | ||||
| Post-retirement obligations | $8.1M | $7.9M | ||||
| Noncurrent liabilities | $7.4M | $4.4M | ||||
| Deferred income taxes | $71.1M | $69.5M | ||||
| Total liabilities | $2.7B | $2.7B | ||||
| Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at December 31, 2025 and 2024 | $2.9M | $2.9M | ||||
| Preferred stock, with $0.01 par value, 120,000 shares authorized; no shares issued at December 31, 2025 and 2024 | $0 | $0 | ||||
| Treasury stock, at cost (1,666 and 2,571 shares at December 31, 2025 and 2024, respectively) | -$17.0M | -$23.4M | ||||
| Additional paid-in capital | $1.3B | $1.2B | ||||
| Retained deficit | -$532.1M | -$610.0M | ||||
| Accumulated other comprehensive loss | -$109.8M | -$208.3M | ||||
| Total equity | $606.0M | $404.9M | $443.7M | $350.2M | ||
| Total liabilities and equity | $3.3B | $3.1B | ||||
| Allowance for uncollectible accounts | $3.0M | $2.5M | ||||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | $0.01 | |||
| Common stock, shares authorized (in shares) | 1.2B shares | 1.2B shares | 1.2B shares | |||
| Common stock, shares issued (in shares) | 286.0M shares | 286.0M shares | ||||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | $0.01 | |||
| Preferred stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | 120.0M shares | |||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||||
| Treasury stock (in shares) | 1.7M shares | 2.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $77.9M | $44.4M | $51.4M |
| Depreciation | $94.9M | $84.3M | $76.6M |
| Amortization of intangible assets | $41.8M | $79.4M | $81.3M |
| Loss on refinancing of debt | $1.5M | $24.2M | $0 |
| Deferred income taxes | $22.0K | $9.4M | $3.4M |
| Share-based compensation expense | $30.9M | $36.8M | $32.2M |
| Accretion expense | $2.3M | $2.6M | $2.4M |
| Unrealized foreign exchange loss (gain) | $9.5M | -$18.3M | $6.1M |
| Unrealized (gain) loss on derivatives not designated as hedging instruments | -$863.0K | $2.2M | -$1.6M |
| Amortization of debt issuance costs | $5.4M | $7.2M | $9.1M |
| Other | -$4.3M | -$5.4M | -$5.3M |
| Accounts receivable | $7.2M | $2.2M | -$21.7M |
| Inventories | -$2.4M | -$4.8M | -$10.0M |
| Other current assets | -$12.9M | $3.6M | $4.0M |
| Accounts payable | $5.2M | -$6.6M | -$5.3M |
| Accrued liabilities | $1.9M | $7.1M | $3.5M |
| Income taxes payable / receivable, net | -$5.5M | $1.5M | $924.0K |
| Other liabilities | $295.0K | -$3.8M | -$1.7M |
| Other long-term assets | $212.0K | -$6.8M | -$238.0K |
| Net cash provided by (used in) operating activities | $287.2M | $224.2M | -$147.7M |
| Purchases of property, plant and equipment | -$138.0M | -$179.1M | -$215.0M |
| Other investing activities | $2.9M | $74.0K | $69.0K |
| Net cash used in investing activities | -$135.1M | -$179.0M | -$214.9M |
| Proceeds from long-term borrowings | $0 | $2.3B | $500.0M |
| Payment of revolving credit facility | $0 | $0 | -$200.0M |
| Payments of debt issuance costs and debt discount | -$4.4M | -$32.1M | -$25.6M |
| Payments of long-term borrowings | -$86.1M | -$2.3B | -$2.5M |
| Buyout of leased facility | $0 | -$6.7M | $0 |
| Shares withheld for employee taxes on equity awards | -$6.6M | -$4.4M | -$4.1M |
| Other financing activities | -$3.5M | -$2.3M | -$1.8M |
| Net cash (used in) provided by financing activities | -$100.5M | -$50.6M | $266.0M |
| Effect of exchange rate changes on cash and cash equivalents | $16.1M | -$17.4M | $2.0M |
| Net increase (decrease) in cash and cash equivalents, including restricted cash | $67.6M | -$22.8M | -$94.6M |
| Cash paid during the period for interest | $164.0M | $179.9M | $173.8M |
| Cash paid during the period for income taxes, net of tax refunds received | $60.9M | $65.8M | $50.2M |
| Purchases of property, plant and equipment included in accounts payable | $25.3M | $10.2M | $16.7M |
No quarter-by-quarter statement was filed.
Corporate structure
Sotera Health Co sits at the top of its group. 40 entities, 14 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Sotera Health Co
- Sachem Head Capital Management LP Filed SCHEDULE 13G/A on Sotera Health Co, latest Oct 9, 2026 (2 filings since May 15, 2026)
- Sculptor Capital LP Filed SCHEDULE 13G/A on Sotera Health Co, latest Aug 14, 2026 (3 filings since Sep 11, 2025)
- Sessa Capital IM, L.P. Filed SCHEDULE 13G/A on Sotera Health Co, latest Aug 14, 2026
- BlackRock Filed SCHEDULE 13G/A on Sotera Health Co, latest Jul 30, 2026 (3 filings since Oct 17, 2025)
- GTCR INVESTMENT XI LLC Filed SCHEDULE 13G/A on Sotera Health Co, latest May 15, 2026 (7 filings since Feb 11, 2022)
- WARBURG PINCUS & CO. Filed SCHEDULE 13G/A on Sotera Health Co, latest May 15, 2026 (6 filings since Feb 14, 2022)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Sotera Health Co, latest Mar 27, 2026 (4 filings since Nov 4, 2024)
- Sessa Capital (Master), L.P. Filed SCHEDULE 13G on Sotera Health Co, latest Feb 17, 2026
- Darsana Capital Partners LP Filed SCHEDULE 13G/A on Sotera Health Co, latest Nov 14, 2025 (2 filings since Sep 13, 2024)
- Sotera Health Co Wilmington, Delaware, United States
- Companhia Brasileira de Esterilização Subsidiary · Brazil
- DEROSS Holding B.V. Subsidiary · Netherlands
- Nelson Laboratories Bozeman, LLC Subsidiary · Delaware, United States
- Nelson Laboratories Fairfield Holdings, LLC Subsidiary · Delaware, United States
- Nelson Laboratories Fairfield, Inc. Subsidiary · New Jersey, United States
- Nelson Laboratories Holdings, LLC Subsidiary · Delaware, United States
- Nelson Laboratories, LLC Subsidiary · Delaware, United States
- Nelson Labs NV Subsidiary · Belgium
- Nordion (Canada) Inc. Subsidiary · Canada
- Nordion (US) Inc. Subsidiary · Delaware, United States
- Nordion US Holdings LLC Subsidiary · Delaware, United States
- Regulatory Compliance Associates Inc. Subsidiary · Delaware, United States
- REVISS Services (UK) Limited Subsidiary · United Kingdom
- RSI Leasing, LLC Subsidiary · California, United States
- Sotera Health Holdings, LLC Subsidiary · Delaware, United States
- Sotera Health Services, LLC Subsidiary · Delaware, United States
- Sterigenics Belgium Fleurus S.A. Subsidiary · Belgium
- Sterigenics Belgium Petit Rechain S.A. Subsidiary · Belgium
- Sterigenics Brasil Participaçãos EIRELI Subsidiary · Brazil
- Sterigenics Costa Rica, S.R.L. Subsidiary · Costa Rica
- Sterigenics Denmark A/S Subsidiary · Denmark
- Sterigenics EO Canada, Inc. Subsidiary · Canada
- Sterigenics France S.A.S. Subsidiary · France
- Sterigenics Germany GmbH Subsidiary · Germany
- Sterigenics Italy S.p.A. Subsidiary · Italy
- and 14 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Sotera Health Co reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Computer equipment and software | $17.1M6 Dec 31, 2025 | $11.4M6 Dec 31, 2024 | +50.0% |
| Operating-lease assets (leased space) | $33.4M6 Dec 31, 2025 | $27.6M6 Dec 31, 2024 | +21.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $344.6M6 Dec 31, 2025 | $277.2M6 Dec 31, 2024 | +24.3% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $1.1B6 Dec 31, 2025 | $1.1B6 Dec 31, 2024 | +2.0% |
| Intangible assets, net (excluding goodwill) | $288.2M6 Dec 31, 2025 | $317.7M6 Dec 31, 2024 | −9.3% |
| Indefinite-lived intangibles (excluding goodwill) | $102.1M6 Dec 31, 2025 | $98.1M6 Dec 31, 2024 | +4.1% |
| Finite-lived intangibles, gross | $386.0M6 Dec 31, 2025 | $928.4M6 Dec 31, 2024 | −58.4% |
| Accumulated amortization | $199.8M6 Dec 31, 2025 | $708.8M6 Dec 31, 2024 | −71.8% |
| Finite-lived intangibles, net | $186.1M6 Dec 31, 2025 | $219.6M10 Dec 31, 2024 | −15.2% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $54.4M6 Dec 31, 2025 | $49.2M6 Dec 31, 2024 | +10.6% |
| Work in process | $2.4M6 Dec 31, 2025 | $929.0K6 Dec 31, 2024 | +162.2% |
| Finished goods | $6.6M6 Dec 31, 2025 | $6.0M6 Dec 31, 2024 | +9.7% |
Properties, in its own words
Our corporate headquarters is in Broadview Heights, Ohio, our Sterigenics headquarters is in Oakbrook, Illinois, our Nelson Labs headquarters is in Taylorsville, Utah and our Nordion headquarters is in Kanata, Ontario, Canada. As of December 31, 2025, we operated 62 facilities in North America, South America, Europe and Asia. The following table identified the number of owned and leased facilities, other than our headquarters listed above. We believe that our facilities are adequate for our current needs and that suitable additional or substitute space will be available as needed to accommodate our operations, subject to securing regulatory and other approvals discussed above.
Segment(1) · Owned Facilities · Owned/LeasedFacilities(2) · Leased Facilities
The rest of Item 2
Sterigenics · 30 · 3 · 15
Nelson Labs · 5 · 1 · 6
Nordion · 1 · — · 1
(1)Seven of our Sterigenics and Nelson Labs facilities are located at the same address but are considered separate facilities because they require separate infrastructure. Two of our Sterigenics facilities are located at the same address but are considered separate facilities because they provide different sterilization modalities and require separate infrastructure.
(2)Owned/leased facilities are comprised of multiple buildings, with some leased and some owned.
Item 2 of the 10-K filed Feb 24, 2026.5
Leadership
Who has led Sotera Health Co, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerAlton Shader May 27, 2026 to now13
- Chief executive officerMichael B. Petras Jr. Nov 20, 2020 to May 27, 202614
- ChairMichael B. Petras Jr. Nov 20, 2020 to now14
- PresidentMichael P. Rutz Nov 20, 2020 to now15
- Chief financial officerJonathan M. Lyons Jul 6, 2023 to now16
- Chief financial officerMichael F. Biehl Jul 26, 2022 to Jul 26, 202217
- Chief financial officerScott J. Leffler Nov 20, 2020 to Mar 4, 202218
Board members and other officers (20)
- Former SVP, GC and Sec.Alexander Dimitrief Apr 2, 2026 to now19
- SVP, GC and SecretaryTerry Hammons Nov 5, 2021 to Mar 4, 202220
- SVP, GC and SecretaryMatthew J. Klaben Nov 20, 2020 to Oct 7, 202221
- Board memberRichard G. Kyle Feb 13, 2026 to now22
- Board memberKenneth D. Krause Mar 20, 2026 to now23
- Board memberAlton Shader May 27, 2026 to now13
- Board memberHoldco L.p. Bull Mar 6, 2024 to now24
- Board memberChristopher Simon Aug 9, 2024 to now25
- Board memberKaren Flynn Nov 21, 2023 to now26
- Board memberRobert Brown Knauss Oct 24, 2022 to now27
- Board memberDavid E. Wheadon May 28, 2021 to now28
- Board memberAnn R. Klee Nov 20, 2020 to now29
- Board memberConstantine S. Mihas Nov 20, 2020 to now30
- Board memberDavid Donnini Nov 20, 2020 to May 29, 202431
- Board memberJames Neary Nov 20, 2020 to now32
- Board memberRuoxi Chen Nov 20, 2020 to now33
- Board memberSean Laurence Cunningham Nov 20, 2020 to now34
- Board memberStephanie Geveda Nov 20, 2020 to May 31, 202235
- Board memberVincent K. Petrella Nov 20, 2020 to now36
- General counselAlexander Dimitrief Nov 8, 2022 to now37
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Companhia Brasileira de Esterilização Brazil4
- DEROSS Holding B.V. Netherlands4
- Nelson Laboratories Bozeman, LLC Delaware4
- Nelson Laboratories Fairfield Holdings, LLC Delaware4
- Nelson Laboratories Fairfield, Inc. New Jersey4
- Nelson Laboratories Holdings, LLC Delaware4
- Nelson Laboratories, LLC Delaware4
- Nelson Labs NV Belgium4
- Nordion (Canada) Inc. Canada4
- Nordion (US) Inc. Delaware4
- Nordion US Holdings LLC Delaware4
- REVISS Services (UK) Limited United Kingdom4
- RSI Leasing, LLC California4
- Regulatory Compliance Associates Inc. Delaware4
- STR C.V. Netherlands4
- Sotera Health Holdings, LLC Delaware4
- Sotera Health LLC Delaware4
- Sotera Health Services, LLC Delaware4
- Sterigenics Belgium Fleurus S.A. Belgium4
- Sterigenics Belgium Petit Rechain S.A. Belgium4
- Sterigenics Brasil Participaçãos EIRELI Brazil4
- Sterigenics Costa Rica, S.R.L. Costa Rica4
- Sterigenics Denmark A/S Denmark4
- Sterigenics EO Canada, Inc. Canada4
All 40 listed subsidiaries
- Sterigenics France S.A.S. France4
- Sterigenics Germany GmbH Germany4
- Sterigenics Italy S.p.A. Italy4
- Sterigenics NV Belgium4
- Sterigenics Radiation Technologies Canada, Inc. British Columbia4
- Sterigenics Radiation Technologies Holdings, LLC Delaware4
- Sterigenics Radiation Technologies IN, Inc. Indiana4
- Sterigenics Radiation Technologies, LLC Delaware4
- Sterigenics S.A.S. France4
- Sterigenics Shanghai E-beam Ltd. China4
- Sterigenics Shanghai ETO Ltd. China4
- Sterigenics Thailand, Ltd. Thailand4
- Sterigenics U.S., LLC Delaware4
- Sterigenics UK Limited United Kingdom4
- Sterigenics, S. de R.L. de C.V. Mexico4
- Unidade de Esterilização Cotia LTDA Brazil4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Sotera Health Topco, Inc.Sep 2, 2020 to Oct 9, 20203
Timeline
- Aug 14, 20268-K Executive or director change38
- Aug 6, 20268-K Results of operations39
- May 27, 2026New chief executive Alton Shader becomes CEO13
- May 22, 20268-K Shareholder vote40
- May 20, 20268-K Entered a material agreement; New debt or obligation41
- May 13, 20268-K Ended a material agreement; Other events42
- May 5, 20268-K Results of operations; Executive or director change43
- Mar 16, 20268-K Executive or director change44
- Mar 6, 20268-K Other events45
- Feb 24, 20268-K Results of operations; Executive or director change46
- Feb 5, 20268-K Executive or director change47
- Jan 12, 20268-K Results of operations; Regulation FD disclosure48
- Nov 10, 20258-K Other events49
- Nov 20, 2020New chief executive Michael B. Petras Jr. becomes CEO14
- Mar 18, 2015Founded Sotera Health Co is founded2
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.24 a share, on Nov 4, 2025.50
When it reported results
- Aug 6, 2026Reported quarterly or annual results39
- May 5, 2026Reported quarterly or annual results43
- Feb 24, 2026Reported quarterly or annual results46
- Jan 12, 2026Reported quarterly or annual results48
- Nov 4, 2025Reported quarterly or annual results51
- Aug 8, 2025Reported quarterly or annual results52
- May 1, 2025Reported quarterly or annual results53
- Feb 27, 2025Reported quarterly or annual results54
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
285 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 67 major events, 126 insider forms, 29 large holders, 43 other. The latest 20:
- Oct 9, 2026SCHEDULE 13G/A EDGAR
- Aug 19, 20264 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 14, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 11, 20264 EDGAR
- Aug 7, 2026144 EDGAR
- Aug 7, 20264 EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 30, 2026SCHEDULE 13G/A EDGAR
- May 29, 2026SD EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20263 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
The 285 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
28 open-market trades by officers, directors and large owners since October 2021: 0 buys and 28 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Petras Michael B. Jr.Executive Chairman | Sale | 1,144,515 | $18.50 | $21.2M | Form 4 |
| Aug 7, 2026 | Rutz Michael PPresident of Sterigenics | Sale | 150,000 | $18.84 | $2.8M | Form 4 |
| May 13, 2026 | Warburg Pincus (Cayman) XI, L.P.Director | Sale | 19,102,952 | $15.17 | $289.8M | Form 4 |
| May 13, 2026 | Warburg Pincus XI, L.P.Director | Sale | 19,102,952 | $15.17 | $289.8M | Form 4 |
| May 13, 2026 | GTCR FUND XI/C LPDirector | Sale | 12,735,301 | $15.17 | $193.2M | Form 4 |
| Mar 6, 2026 | Warburg Pincus Partners GP LLCDirector | Sale | 15,000,000 | $15.27 | $229.1M | Form 4 |
| Mar 6, 2026 | Warburg Pincus Partners II, L.P.Director | Sale | 15,000,000 | $15.27 | $229.1M | Form 4 |
| Mar 6, 2026 | GTCR CO-INVEST XI LPDirector | Sale | 10,000,000 | $15.27 | $152.7M | Form 4 |
| Dec 8, 2025 | Petras Michael B. Jr.Executive Chairman | Sale | 750,000 | $16.45 | $12.3M | Form 4 |
| Dec 3, 2025 | WARBURG PINCUS LLCDirector | Sale | 9,720,000 | $16.33 | $158.7M | Form 4 |
| Dec 3, 2025 | Warburg Pincus Partners GP LLCDirector | Sale | 9,720,000 | $16.33 | $158.7M | Form 4 |
| Dec 3, 2025 | GTCR FUND XI/A LPDirector | Sale | 6,480,000 | $16.33 | $105.8M | Form 4 |
| Nov 10, 2025 | Warburg Pincus Private Equity XI-C, L.P.Director | Sale | 18,000,000 | $15.65 | $281.7M | Form 4 |
| Nov 10, 2025 | Warburg Pincus Partners II, L.P.Director | Sale | 18,000,000 | $15.65 | $281.7M | Form 4 |
| Nov 10, 2025 | GTCR FUND XI/A LPDirector | Sale | 12,000,000 | $15.65 | $187.8M | Form 4 |
| Sep 5, 2025 | Warburg Pincus XI-C, LLCDirector | Sale | 12,000,000 | $15.11 | $181.3M | Form 4 |
| Sep 5, 2025 | WARBURG PINCUS & CO.Director | Sale | 12,000,000 | $15.11 | $181.3M | Form 4 |
| Sep 5, 2025 | GTCR INVESTMENT XI LLCDirector | Sale | 8,000,000 | $15.11 | $120.9M | Form 4 |
| Aug 22, 2025 | Rutz Michael PPresident of Sterigenics | Sale | 126,611 | $16.38 | $2.1M | Form 4 |
| Sep 6, 2024 | Warburg Pincus Private Equity XI-C, L.P.Director | Sale | 15,000,000 | $15.03 | $225.4M | Form 4 |
All 28 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Sachem Head Capital Management LPSCHEDULE 13G/A, 2 filings May 15, 2026 to Oct 9, 202655
- Sculptor Capital LPSCHEDULE 13G/A, 3 filings Sep 11, 2025 to Aug 14, 202656
- Sessa Capital IM, L.P.SCHEDULE 13G/A, 1 filing Aug 14, 202657
- BlackRockSCHEDULE 13G/A, 3 filings Oct 17, 2025 to Jul 30, 202658
- GTCR INVESTMENT XI LLCSCHEDULE 13G/A, 7 filings Feb 11, 2022 to May 15, 202659
- WARBURG PINCUS & CO.SCHEDULE 13G/A, 6 filings Feb 14, 2022 to May 15, 202660
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Nov 4, 2024 to Mar 27, 202661
- Sessa Capital (Master), L.P.SCHEDULE 13G, 1 filing Feb 17, 202662
- Darsana Capital Partners LPSCHEDULE 13G/A, 2 filings Sep 13, 2024 to Nov 14, 202563
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Michael B. Petras, Jr.Chairman and CEO | $1.1M | $10.7M64 | |
| 2025 | Jonathan LyonsSVP, CFO | $536.5K | $3.1M64 | |
| 2025 | Alexander DimitriefFormer SVP and General Counsel | $600.0K | $2.5M64 | |
| 2025 | Michael P. RutzPresident of Sterigenics | $500.0K | $2.2M64 | |
| 2024 | Michael B. Petras, Jr.Chairman and CEO | $1.1M | $10.4M64 | |
| 2024 | Michael P. RutzPresident of Sterigenics | $491.9K | $2.5M64 | |
| 2024 | Alexander DimitriefFormer SVP and General Counsel | $600.0K | $2.4M64 | |
| 2024 | Jonathan LyonsSVP, CFO | $493.3K | $2.1M64 | |
| 2023 | Michael B. Petras, Jr.Chairman and CEO | $1.1M | $9.7M64 | |
| 2023 | Jonathan LyonsSVP, CFO | $237.5K | $2.2M64 | |
| 2023 | Michael P. RutzPresident of Sterigenics | $464.6K | $2.0M64 | |
| 2023 | Alexander DimitriefFormer SVP and General Counsel | $600.0K | $862.2K64 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Sessa Capital IM, L.P. | 27,050,000 | $480.1M | 8.3% | +4,000,000 |
| Darsana Capital Partners LP | 27,000,000 | $479.2M | 2.2% | +1,000,000 |
| BlackRock, Inc. | 24,148,424 | $428.6M | 0.0% | +3,298,845 |
| Sculptor Capital LP | 24,000,000 | $426.0M | 6.1% | +2,282,272 |
| Sachem Head Capital Management LP | 15,560,000 | $276.2M | 5.7% | +3,915,000 |
| Vanguard Capital Management LLC | 12,170,699 | $216.0M | 0.0% | +1,435,693 |
| Vanguard Portfolio Management LLC | 11,946,341 | $212.0M | 0.0% | +1,337,624 |
| Aqr Capital Management LLC | 10,734,313 | $186.4M | 0.1% | +4,013,550 |
| Jupiter Topco LLC | 8,402,106 | $149.1M | 0.1% | New |
| State Street Corp | 8,324,321 | $147.8M | 0.0% | +1,302,695 |
| Fmr LLC | 6,173,320 | $109.6M | 0.0% | +6,144,727 |
| Two Seas Capital LP | 5,836,053 | $103.6M | 4.0% | −187,318 |
| Voss Capital, LP | 5,825,000 | $103.4M | 5.2% | +953,730 |
| Dimensional Fund Advisors LP | 5,799,870 | $102.9M | 0.0% | +280,995 |
| Geode Capital Management, LLC | 5,219,965 | $92.7M | 0.0% | +580,066 |
| Irenic Capital Management LP | 5,141,822 | $91.3M | 6.6% | +782,474 |
| DME Capital Management, LP | 4,135,515 | $73.4M | 1.9% | +2,069,835 |
| Lakewood Capital Management, LP | 3,979,581 | $70.6M | 3.7% | −125,000 |
| Norges Bank | 3,512,499 | $62.3M | 0.0% | New |
| ION Fund Management Ltd | 3,343,648 | $59.3M | 7.0% | +2,150,258 |
| Morgan Stanley | 3,075,334 | $54.6M | 0.0% | +1,012,853 |
| Charles Schwab Investment Management Inc | 2,803,452 | $49.8M | 0.0% | +310,179 |
| Dendur Capital LP | 2,770,000 | $49.2M | 2.9% | New |
| Ancora Advisors LLC | 2,683,637 | $47.6M | 0.9% | New |
| Gotham Asset Management, LLC | 2,206,457 | $39.2M | 0.1% | +1,059,576 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Sotera Health Co is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSotera Health Co1
- CIK0001822479
- Employer ID (EIN)47-35311615
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)8090 Services-Misc Health & Allied Services, NEC1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address9100 South Hills Blvd, Suite 300, Broadview Heights, OH 441471
- Phone440-262-14101
- Shares outstanding285,374,795 as of Jul 30, 202612
- Public float$1.7B as of Jun 30, 20255
- AuditorErnst & Young LLP, Cleveland, Ohio PCAOB ID 42; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceSep 2, 20201
- Filings382 in all: 4 (141), 8-K (76), 3 (28), SCHEDULE 13G/A (18), 10-Q (17), 424B7 (12), CORRESP (9), 144 (8)1
All 34 form types
DEFA14A (8), 10-K (6), DEF 14A (6), SC 13G/A (6), ARS (4), S-1/A (4), SCHEDULE 13G (4), SD (4), UPLOAD (4), SC 13G (3), 3/A (2), 424B4 (2), 8-K/A (2), DRS (2), DRS/A (2), EFFECT (2), S-1 (2), SEC STAFF LETTER (2), 8-A12B (1), CERT (1), DEFR14A (1), DRSLTR (1), FWP (1), PRE 14A (1), S-3ASR (1), S-8 (1)
- Latest filingsAnnual report (10-K) Feb 24, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 8, 2026
Latest 8-K (8-K) Aug 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.01 par value per share | SHC | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Sotera Health Co names in Item 1A of its 10-K filed Feb 24, 2026: 45 risks under these headings, as written.5
- Risks Related to the Company
- We depend on a limited number of counterparties to provide the materials and resources we need to operate our business. Any disruption in the availability of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of geopolitical instability or sanctions against Russia by the United States, Canada, the United Kingdom and/or the European Union, or sanctions by Russia against those countries, may have a material adverse effect on our operating results.
- We may be subject to evolving changes in environmental, health and safety regulations, which may negatively impact our business.
- Safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials, such as EO and Co-60, may result in accidents or liabilities that materially affect our results of operations.
- Potential health risks associated with the use of EO may subject us to future liability claims and associated adverse effects.
- We are currently defending certain litigation, and we are likely to be subject to additional litigation in the future.
- We have received an adverse judgment and may in the future receive other adverse judgments in litigation relating to our use, emissions and releases of EO. Despite our belief that these claims are not supported by the science and are otherwise without merit, we have entered and may in the future enter into agreements to settle claims relating to our use, emissions and releases of EO. The resolution of these matters by litigation or settlement may have a negative impact on our financial condition and liquidity in the near and long term.
- Allegations of our failure to properly perform our services may expose us to potential product liability claims, recalls, penalties and reputational harm or could otherwise cause a material adverse effect on our business.
- We are subject to extensive regulatory requirements and routine regulatory audits in our operations. We must receive certain permits, licenses and/or regulatory clearance or approval for our operations. Compliance with these regulations is costly, and failure to comply with all laws and regulations or to receive or maintain permits, licenses, clearances or approvals may impact our revenues, profitability, financial condition or value. We may face liability and reputational risks even if we comply with all laws and regulations.
- Safety risks associated with the transportation of potentially hazardous materials, such as EO and Co-60, may result in accidents or liabilities that materially affect our results of operations.
- Industry trends could impact the demand for our products and services and could have a material adverse effect on our business.
- Our business is highly competitive, and if we fail to compete successfully, our business, prospects, financial condition or results of operations may be materially adversely affected.
The other 34 risks
- The price of our input costs, including labor, raw materials and energy, are subject to inflation and other market risks and our ability to pass through increases in our input costs is highly dependent on market conditions.
- Our operations are subject to a variety of business continuity hazards and risks, including supply chain disruptions due to geopolitical uncertainty and federal government shutdowns, and our reliance on the use and sale of products and services from single locations, any of which could interrupt production or operations or otherwise adversely affect our performance, results of operations or value.
- We may be adversely affected by global and regional economic and political instability.
- If we are unable to increase capacity at existing facilities and build new facilities in a timely and cost-effective manner, we may not achieve our expected revenue growth or profitability or such revenue growth and profitability, if any, could be delayed.
- We depend upon our ability to attract and retain highly skilled employees. If we fail to attract and retain the talent required for our business, our operations could be adversely affected and our business could be materially harmed.
- We occupy many of our facilities under long-term leases, and we may be unable to renew our leases at the end of their terms.
- We conduct sales and distribution operations on a worldwide basis and are subject to a variety of risks associated with doing business outside the United States.
- We are subject to significant regulatory oversight of our import and export operations due to the nature of some of our product offerings.
- Severe health events or environmental events, including impacts from climate change, and natural disasters, could have material adverse effects on our business, financial condition and results of operations.
- Our business may be subject to system interruptions, cybersecurity incidents and unauthorized data disclosures.
- We may be incorporating AI technologies into our products, services and processes, which may present business, compliance and reputational risks.
- Part of our growth strategy is to pursue strategic transactions, including acquisitions, which subjects us to risks that could harm our business and we may not be able to find suitable acquisition targets or integrate strategic acquisitions successfully into our existing business.
- Our internal control over financial reporting may not be effective and our independent registered public accounting firm may not be able to certify as to their effectiveness, which could have a significant and adverse effect on our business and reputation.
- We rely on intellectual property rights to maintain our competitive position and third parties have claimed in the past, and may claim in the future, that we infringe or misappropriate their intellectual property rights.
- We are subject to complex and rapidly evolving data privacy and security laws and regulations, and any ineffective compliance efforts with such laws and regulations may adversely impact our business.
- We have a history of net losses and may not maintain profitability in future periods.
- We may incur impairment charges on our goodwill and other intangible assets with indefinite lives as well as other long-lived assets and intangible assets with definite lives, which could adversely affect our business, financial condition or results of operations.
- Unionization efforts and labor regulations could materially increase our costs or limit our flexibility.
- Government or private civil antitrust actions could harm our business, prospects, financial condition or results of operations.
- We may have greater than anticipated tax liabilities, which could harm our business, revenue and financial results.
- Risks Related to Our Indebtedness and Liquidity
- Our significant degree of leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to challenges facing our Company or broader changes in our industry or the economy, expose us to interest rate risk and prevent us from meeting our obligations under our existing and future indebtedness.
- The agreements governing our debt, including the Secured Notes, contain various covenants that impose restrictions on us and limit our flexibility in operating our business.
- Our cash flows may not be sufficient to service our indebtedness, and if we are unable to satisfy our obligations under our indebtedness, we may be required to seek other financing alternatives, which may not be successful.
- A lowering or withdrawal of the ratings assigned to our debt by rating agencies may increase our future borrowing costs and reduce our access to capital.
- SHH is a holding company, and therefore its ability to make any required payment on our credit agreements depends upon the ability of its subsidiaries to pay it dividends or to advance it funds.
- Risks Related to Ownership of Our Common Stock
- The market and trading volume of our common stock may be volatile, and you could lose all or part of your investment.
- The future issuance of additional common stock in connection with our incentive plans, acquisitions or otherwise will dilute all other stockholdings.
- Future offerings of debt or equity securities by us may adversely affect the market price of our common stock.
- A sale of a substantial number of shares of our common stock, or the perception that such sales might occur, may cause the price of our common stock to decline.
- The interests of our Sponsors may differ from the interests of other stockholders of the Company.
- Certain of our stockholders have the right to engage or invest in the same or similar businesses as us.
- Anti-takeover provisions in our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and the Stockholders Agreement, as well as Delaware law, could discourage a change in control of our company or a change in our management.
- Our Amended and Restated Certificate of Incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ abilities to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- We do not anticipate paying any dividends on our common stock in the foreseeable future, and, consequently, our stockholders’ ability to achieve a return on their investment depends on appreciation in the price of our common stock.
Legal proceedings
From time to time, we may be subject to various legal proceedings arising in the ordinary course of our business, including claims relating to personal injury, property damage, workers’ compensation, employee safety and our disclosures as a Nasdaq-listed, publicly-traded company. In addition, from time to time, we receive communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which we operate. At this time, and except as disclosed herein, we are unable to predict the outcome of, and cannot reasonably estimate the impact of, any pending litigation matters, matters concerning allegations of non-compliance with laws or regulations and matters concerning other allegations of other improprieties, or the incidence of any such matters in the future. Information regarding our legal proceedings is included below.
Legal Proceedings Described in Note 19, “Commitments and Contingencies,” of Our Consolidated Financial Statements
Note 19, “Commitments and Contingencies,” to our consolidated financial statements for the year ended December 31, 2025 contained in this Annual Report on Form 10-K includes information on legal proceedings that constitute material contingencies for financial reporting purposes that could have a material effect on our financial condition or results of operations. This Item should be read in conjunction with Note 19, “Commitments and Contingencies,” for information regarding the following legal proceedings, which information is incorporated into this Item 3 by reference:
•Ethylene Oxide Tort Litigation – California, Georgia, Illinois and New Mexico;
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARMichael P. Rutz, President
- 16
- 17
- 18
- 19
- 20SEC EDGARTerry Hammons, SVP, GC and Secretary
- 21
- 22SEC EDGARRichard G. Kyle, Board member
- 23SEC EDGARKenneth D. Krause, Board member
- 24SEC EDGARHoldco L.p. Bull, Board member
- 25SEC EDGARChristopher Simon, Board member
- 26SEC EDGARKaren Flynn, Board member
- 27SEC EDGARRobert Brown Knauss, Board member
- 28SEC EDGARDavid E. Wheadon, Board member
- 29SEC EDGARAnn R. Klee, Board member
- 30SEC EDGARConstantine S. Mihas, Board member
- 31SEC EDGARDavid Donnini, Board member
- 32SEC EDGARJames Neary, Board member
- 33SEC EDGARRuoxi Chen, Board member
- 34
- 35SEC EDGARStephanie Geveda, Board member
- 36SEC EDGARVincent K. Petrella, Board member
- 37SEC EDGARAlexander Dimitrief, General counsel
- 38SEC EDGARExecutive or director change
- 39SEC EDGARResults of operations
- 40SEC EDGARShareholder vote
- 41
- 42
- 43
- 44SEC EDGARExecutive or director change
- 45SEC EDGAROther events
- 46
- 47SEC EDGARExecutive or director change
- 48
- 49SEC EDGAROther events
- 50NasdaqNasdaq calendar
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64